Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement

Author(s): Sandra M. Martín-Guerrero, Josefa León, Rosa Quiles-Perez, Laura Belmonte, David Martin-Oliva, Ángeles Ruiz-Extremera, Javier Salmerón, José Antonio Muñoz-Gámez*.

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 20 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.

Keywords: Biomarker, carcinogenesis, gastrointestinal cancer, PARP inhibitors, poly (ADP-ribose) polymerase-1 (PARP-1), synthetic lethality.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 20
Year: 2017
Page: [2156 - 2173]
Pages: 18
DOI: 10.2174/0929867324666170316115039
Price: $58

Article Metrics

PDF: 16
HTML: 5
EPUB: 1
PRC: 1